Abstract Purpose of Review Cardiac myosin inhibitors (CMIs) and activators are emerging
therapies for hypertrophic cardiomyopathy (HCM) and heart failure with reduced ejection …

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy
worldwide and causes significant morbidity and mortality. For decades, medical treatment …

Hypertrophic cardiomyopathy (HCM) is an inherited condition with an estimated global
prevalence of 1 in 500 adults and is characterized by left ventricular, non-dilated …

We aimed to assess the overall clinical impact of cardiac myosin inhibitors in hypertrophic
cardiomyopathy (HCM). We performed a meta-analysis of published trials assessing the …

Hypertrophic cardiomyopathy (HCM) is frequently caused by pathogenic variants in genes
encoding sarcomere proteins and is characterized by left ventricular (LV) hypertrophy …

First-in-class cardiac myosin inhibitor reduces symptoms of HCM | Nature Reviews Cardiology
Skip to main content Thank you for visiting nature.com. You are using a browser version with …

Left ventricular systolic dysfunction is the hallmark pathology in heart failure with reduced
ejection fraction. Increasing left ventricular contractility with beta-adrenergic receptor …

There is now robust clinical trial evidence base to support the use of mavacamten for
patients with symptomatic obstructive hypertrophic cardiomyopathy. Generation of long-term …

Objective: To review the current literature on the efficacy and safety of cardiac myosin
inhibitors (CMIs) for the treatment of hypertrophic cardiomyopathy (HCM). Data Sources: A …

During the progression of heart failure (HF), phases of chronic compensation and acute
decompensation alternate and the clinical status worsens during the acute phase. At the …